THE IMMUNO WEBINARS ANNOUNCES

Nov 23th (Tuesday), 12pm

The long-standing interests of our laboratory center on identifying specific mechanisms of human anti-tumor immunity and cancer immunosurveillance. We study T cell and antibody repertoire in cancer patients and in healthy individuals at risk for cancer and factors that influence that repertoire. We were the first to identify a human tumor antigen recognized by human T cells and antibodies, the epithelial mucin MUC1. We showed that tumors express an abnormal form of MUC1 that is recognized by the immune system as a foreign rather than a self-antigen. Studies in mice and primates showed that MUC1 was immunogenic and that anti-MUC1 immune responses can reject tumors. These studies supported multiple clinical trials of a MUC1 vaccine in patients with breast, Colon and pancreatic cancer. Most recently, we began testing a MUC1 vaccine for cancer prevention in individuals diagnosed with MUC1+ premalignant lesions.

Dr. Olivera J. Finn

Programa de Pós-Graduação em Imunologia | Pensando e Inovando em Imunologia
Universidade de São Paulo

Acesso: https://zoom.us/j/97489200451?pwd=akJhWGZhandjekRyd0t1WHJBUFBJUT09
@ppgimunousp https://www.facebook.com/ppgimunousp/

Organizadores: Paula P. Freire, Letícia G. Pontes and Gustavo P. Amarante-Mendes